The General Court decided that the first plea in law put forward by the applicant and appellant was inadmissible, as the latter had failed to allege any infringement of the formal requirements of Article 56(2) of Regulation No 207/2009, in conjunction with Rule 37(b)(iv) of Regulation No 2868/95, the examination of the complaint was limited to examining whether there had been genuine use, and the Board of Appeal was therefore not required to consider the propriety of the application for revocation.
A klinikai vizsgálatok során nagyon gyakran jelezték a Parkinson-kór tünetegyüttesének és a hallucinációknak a romlását, gyakrabban, mint placebo-kezelés mellett (lásd #. # pont), és a pszichotikus tünetek kezelésében az olanzapin nem volt hatékonyabb a placebónáleurlex-diff-2018-06-20 eurlex-diff-2018-06-20